Dewpoint therapeutics logo
WebOct 13, 2024 · Oct. 13, 2024, 06:00 AM. - Nathwani joins Dewpoint after serving as Chief Medical Officer, Chief Digital Officer, and Executive Committee member at Sanofi. BOSTON, Oct. 13, 2024 /PRNewswire ... WebJan 30, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A ...
Dewpoint therapeutics logo
Did you know?
WebOct 13, 2024 · BOSTON, Oct. 13, 2024 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Ameet Nathwani, … WebWe combine expertise from complementary state-of-the-art experimental technologies with a powerful AI platform to develop powerful therapies across a broad range of therapeutic … BOSTON, Nov. 14, 2024 — Dewpoint Therapeutics Inc. today announced the … Dewpoint Therapeutics GmbH Industriepark Höchst, G879 65926 Frankfurt am Main … Four years since our founding, we are partnering with the world’s leading …
WebJan 12, 2024 · Dewpoint Therapeutics employees attributed a compensation and benefits rating of 3.6/5 stars to their company. Read what they think about their salaries on our Compensation FAQ page for Dewpoint Therapeutics . WebNovocure shakes up C-suite after successful trial of tumor-treating electric fields in lung cancer. Jan 20, 2024 10:46am.
WebFunding. Dewpoint Therapeutics has raised a total of $287M in funding over 3 rounds. Their latest funding was raised on Feb 3, 2024 from a Series C round. Dewpoint Therapeutics is funded by 16 investors. SoftBank Vision Fund and Mirae Asset Capital are the most recent investors. WebNovocure shakes up C-suite after successful trial of tumor-treating electric fields in lung cancer. Jan 20, 2024 10:46am.
WebMar 22, 2024 · First biomolecular condensates research collaboration to identify drug candidates related to insulin resistance and diabetic complications ; Dewpoint is eligible to receive up to $55 million near term and up to $690 million of clinical, commercial and sales milestones plus royalties across two commercial products; BOSTON, March 22, 2024 …
WebDewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and … north face class v water trunksWebJoin us. Dewpoint is the first company to apply this emerging understanding of biomolecular condensates to advance a revolutionary approach to drug discovery. We believe that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration ... north face class v camp hatWebIntellia Therapeutic’s stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CRISPR gene-editing system, has seen a fall of 31% in a month, while it’s down 69% this year. By... north face city trenchnorth face class v shortsWebUCB. May 2024 - Aug 20244 months. Cambridge, Massachusetts, United States. • Maintained multiple cultures of mammalian cell lines (HEK293, … how to save data in edgeWebJan 6, 2024 · Dive Brief: Dewpoint Therapeutics, a young drug company focused on an emerging field of research known as biomolecular condensates, said Wednesday that it is teaming up with Pfizer to develop new treatments for a rare kind of muscular dystrophy. north face classic backpacksWebNov 14, 2024 · BOSTON, Nov. 14, 2024 /PRNewswire/ -- Dewpoint Therapeutics Inc. today announced the U.S. Patent and Trademark Office (USPTO) issued the patent "Methods of Characterizing Condensate-Associated... north face class v pullover